ProQR Therapeutics NV (ProQR Therapeutics NV) LT-Debt-to-Total-Asset : 0.11 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ProQR Therapeutics NV's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.11.

ProQR Therapeutics NV's long-term debt to total assets ratio declined from Mar. 2023 (0.11) to Mar. 2024 (0.11). It may suggest that ProQR Therapeutics NV is progressively becoming less dependent on debt to grow their business.

ProQR Therapeutics NV LT-Debt-to-Total-Asset Historical Data

The historical data trend for ProQR Therapeutics NV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV LT-Debt-to-Total-Asset Chart

ProQR Therapeutics NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.11

0.32

0.26

0.11

0.13

ProQR Therapeutics NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.12	0.12	0.13	0.11

ProQR Therapeutics NV LT-Debt-to-Total-Asset Calculation

ProQR Therapeutics NV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	19.76	/	150.363
	=	0.13

ProQR Therapeutics NV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	14.536	/	134.648
	=	0.11

ProQR Therapeutics NV (NAS:PRQR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ProQR Therapeutics NV LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ProQR Therapeutics NV (ProQR Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (NAS:PRQR) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

0PQ:Germany

Address

Zernikedreef 9, Leiden, ZH, NLD, 2333 CK

Website

https://www.proqr.com

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.